普利制药(300630) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥187,782,077.49, a decrease of 22.90% compared to the adjusted revenue of ¥518,193,841.85 in the same period last year[5] - The net profit attributable to shareholders for Q3 2024 was a loss of ¥41,457,666.78, representing a decline of 1,171.62% compared to the adjusted profit of ¥134,354,740.37 in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥52,497,552.83, a decrease of 145.33% from the adjusted profit of ¥116,215,968.02 in the same period last year[5] - The net profit for the third quarter of 2024 was -98,270,117.53 CNY, compared to a profit of 93,692,084.38 CNY in the same period last year[25] - The net profit margin showed a loss of ¥137,448,360.01 compared to a loss of ¥72,791,799.15 in the previous period, indicating a worsening of profitability[24] - The company reported a significant decrease in cash received from sales of goods and services, totaling 532,183,358.23 CNY, down from 1,054,658,810.56 CNY year-on-year, a decline of approximately 49.6%[26] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥6,286,709,073.07, reflecting a decrease of 0.51% from the previous year[5] - The equity attributable to shareholders at the end of the reporting period was ¥2,906,225,473.18, down 3.35% from the previous year[5] - The total assets decreased slightly to ¥6,254,359,593.45 from ¥6,286,709,073.07, a decline of about 0.51%[22] - Current liabilities decreased to ¥1,388,333,284.69 from ¥1,647,924,437.13, a reduction of approximately 15.7%[20] - The company's total liabilities increased to ¥3,445,462,134.40 from ¥3,380,483,599.89, an increase of approximately 1.9%[22] Cash Flow - The company reported a net cash flow from operating activities of -¥174,189,714.31 for the year-to-date, a decline of 227.48% compared to the previous year[5] - The total cash inflow from operating activities was 691,861,462.93 CNY, down from 1,211,015,921.37 CNY year-on-year, representing a decrease of approximately 42.8%[26] - The net cash flow from operating activities was -174,189,714.31 CNY, contrasting with a positive cash flow of 136,637,661.60 CNY in the previous year[26] - The cash inflow from investment activities totaled 220,589,165.31 CNY, while cash outflow was 251,779,399.84 CNY, resulting in a net cash flow of -31,190,234.53 CNY[27] - The cash inflow from financing activities was 882,000,000.00 CNY, compared to 970,011,770.00 CNY in the previous year, indicating a decrease of about 9.1%[27] - The net cash flow from financing activities was 210,308,344.38 CNY, an increase from 89,554,093.55 CNY year-on-year[27] - The ending balance of cash and cash equivalents was 271,677,120.41 CNY, down from 343,961,158.86 CNY at the end of the previous year[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,860, with the largest shareholder holding 32.77% of the shares[12] - The largest shareholder, Fan Minhua, holds 148,027,509 shares, representing 32.77% of the total shares[12] Operational Changes - The company experienced a 49.65% increase in inventory, totaling ¥537,311,112.88, primarily due to increased stocking[9] - The company's fixed assets increased by 36.59% to ¥1,817,428,667.79, mainly due to the transfer of construction in progress to fixed assets[9] - Sales expenses rose by 47.10% to approximately ¥264.31 million, attributed to increased promotional costs[10] - Research and development expenses decreased by 37.60% to approximately ¥143.43 million, as the company optimized its R&D strategy based on market conditions[10] - Research and development expenses for the period were ¥143,428,252.26, down from ¥229,840,778.19, a decrease of approximately 37.5%[24] Regulatory and Compliance Issues - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[3] - The company is currently cooperating with investigations related to alleged violations of information disclosure laws, which may lead to adjustments in prior financial statements[15] - There is a risk of forced delisting due to potential administrative penalties from the China Securities Regulatory Commission[16] - The company has not yet completed a full audit of the financial statements following the correction of prior accounting errors[4] - The company has not undergone an audit for the third quarter report[28]